Beta Bionics, Inc.
HealthcareNASDAQ:BBNX · NASDAQ Global Market
-$0.16 today
Vol 1.32M · Avg 0.97M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-25.5%
avg -167.7%
ROIC
-23.9%
avg -83.2%
ROA
-22.3%
avg -70.3%
Analysis
ROA is currently the strongest return metric at -22.3% versus its period average of -70.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sean T. Saint | President, Chief Executive Officer & Director | $1.63M | — | 50 | $420,937.00 | 0.94% |
Stephen H. Feider | Chief Financial Officer, Treasurer & Secretary | $832,378.00 | — | 36 | $166,053.00 | 0.37% |
Mike Mensinger | Chief Product Officer | $789,556.00 | — | 48 | $184,415.00 | 0.41% |
Mark Hopman | Chief Commercial Officer | $559,533.00 | — | 48 | $130,612.00 | 0.29% |
Blake Beber | Head of Investor Relations | — | — | — | — | — |
Steven Russell | Chief Medical Officer | — | — | 57 | $173,849.00 | 0.39% |
David Henderson | Vice President of Operations | — | — | — | — | — |
Kevin Meinert | Vice President of Legal & Business Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
50
$3.58M
Net Sentiment
$3.58M
Net selling
Most Active
Feider Stephen
13 transactions
1–10 of 50
Analysis
Insiders reported 0 buys worth $0.00 and 50 sells worth $3.58M over the last 12 months. That adds up to net selling of $3.58M. Feider Stephen was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | +724.3% | +36.0% (5yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Recent growth has been strongest in Revenue at +724.3% over three years. Forward estimates point to Revenue at +36.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Terns Pharmaceuticals, Inc.
TERN
$4.77B
Dynavax Technologies Corporation
DVAX
$1.82B
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.69B
STAAR Surgical Company
NASDAQ:STAA
$1.41B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
Precigen, Inc.
NASDAQ:PGEN
$1.34B
Immatics N.V.
NASDAQ:IMTX
$1.26B
Tourmaline Bio, Inc.
TRML
$1.23B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Who manages BBNX?
Beta Bionics, Inc. (BBNX) lists 8 active executives. The top listed executive is Blake Beber, Head of Investor Relations.
Are BBNX insiders buying or selling?
Recent insider activity shows net buying of $10.23M.
Explore More
Continue the stock analysis
Jump to another research area for this company.